Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of palonosetron alone for prevention of chemotherapy-induced nausea and vomiting in untreated aggressive non-Hodgkin lymphoma
2006-003189-33Phase 2Completed
- Sponsor
- Gruppo Italiano Studio Linfomi
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Gruppo Italiano Studio Linfomi. Primary endpoints: Overall complete response rate and Efficacy and safety of single-dose intravenous palonosetron. Started May 2009; status: completed.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2006-003189-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003189-33.